Weekly Investment Analysts’ Ratings Changes for Synergy Pharmaceuticals (SGYP)

Synergy Pharmaceuticals (NASDAQ: SGYP) has recently received a number of price target changes and ratings updates:

  • 1/25/2018 – Synergy Pharmaceuticals had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $10.00 price target on the stock. They wrote, “FDA approves Trulance IBS-C sNDA, as anticipated. SGYP announced today that the FDA approved the sNDA for Trulance as a treatment for irritable bowel syndrome with constipation (IBS-C). Based on the nature of the supporting data and the drug’s benign side effect profile, we suspect most investors viewed the approval as highly likely.””
  • 1/23/2018 – Synergy Pharmaceuticals was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 1/22/2018 – Synergy Pharmaceuticals had its “hold” rating reaffirmed by analysts at Oppenheimer Holdings Inc..
  • 1/8/2018 – Synergy Pharmaceuticals was given a new $7.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 1/5/2018 – Synergy Pharmaceuticals had its “market perform” rating reaffirmed by analysts at Oppenheimer Holdings Inc.. They now have a $10.00 price target on the stock.
  • 1/5/2018 – Synergy Pharmaceuticals had its “market perform” rating reaffirmed by analysts at CIBC.
  • 1/5/2018 – Synergy Pharmaceuticals was downgraded by analysts at Citigroup Inc to a “market perform” rating.
  • 1/4/2018 – Synergy Pharmaceuticals was downgraded by analysts at Oppenheimer Holdings Inc. from an “outperform” rating to a “market perform” rating.
  • 12/22/2017 – Synergy Pharmaceuticals was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 12/4/2017 – Synergy Pharmaceuticals was given a new $7.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.

Shares of Synergy Pharmaceuticals Inc (NASDAQ SGYP) traded down $0.07 during trading on Monday, hitting $2.24. 6,131,939 shares of the company were exchanged, compared to its average volume of 7,490,000. The company has a current ratio of 4.26, a quick ratio of 3.88 and a debt-to-equity ratio of -68.13. The firm has a market capitalization of $552.52, a price-to-earnings ratio of -1.93 and a beta of 1.22. Synergy Pharmaceuticals Inc has a fifty-two week low of $1.68 and a fifty-two week high of $7.15.

Synergy Pharmaceuticals (NASDAQ:SGYP) last released its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.06. The business had revenue of $5.01 million for the quarter, compared to analyst estimates of $4.53 million. During the same period in the prior year, the firm posted ($0.22) EPS. equities analysts anticipate that Synergy Pharmaceuticals Inc will post -1.03 earnings per share for the current fiscal year.

In other Synergy Pharmaceuticals news, major shareholder Paulson & Co. Inc. sold 8,750,000 shares of Synergy Pharmaceuticals stock in a transaction on Friday, November 10th. The shares were sold at an average price of $2.82, for a total transaction of $24,675,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 3.80% of the stock is currently owned by insiders.

Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.

Receive News & Ratings for Synergy Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply